Bromocriptine SRO is a new galenic preparation which allows a slow release of the drug and the maintaining of more stable plasma levels of drug. Two groups of patients with a diagnosis of Parkinson's disease, 7 'de novo' and 8 with fluctuations in motor performance were studied. Patients were followed up to three months by means of clinical ratings every month. Results of the study show an improvement of disability in the 'de novo' and an increase in the number of hours spent in the 'on' passage with respect to 'off' phase in the fluctuating patients. No significant side effects were recorded.
|Number of pages||6|
|Journal||New Trends in Clinical Neuropharmacology|
|Publication status||Published - 1990|
ASJC Scopus subject areas
- Clinical Neurology